Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07PNC
|
|||
| Former ID |
DPR000085
|
|||
| Drug Name |
Organon
|
|||
| Synonyms |
Allylestrenol; Allyloestrenol; Allyloestrenolum; Gestanin; Gestanol; Gestanon; Gestanyn; Orageston; Perselin; Turinal; Allilestrenolo [DCIT]; Alilestrenol [INN-Spanish]; Allylestrenol [INN:JAN]; Allylestrenol(jan); Allylestrenolum [INN-Latin]; Gestanon-r; Perselin (TN); Allylestrenol (JAN/INN); (17beta)-17-prop-2-en-1-ylestr-4-en-17-ol; (8R,9S,10R,13S,14S,17R)-13-methyl-17-prop-2-enyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol; 17-(2-Propenyl)estr-4-en-17-ol; 17-Hydroxy-17-alpha-allyl-4-estrene; 17-alpha-Allyl-17-beta-hydroxy-4-estrene; 17-alpha-Allyl-17-beta-hydroxy-delta(sup 4)-estren; 17-alpha-Allyl-3-deoxy-19-nortestosterone; 17-alpha-Allyl-4-oestrene-17-beta-ol; 17-alpha-Allylestr-4-en-17-beta-ol; 17-alpha-Allylhydroxy-19-nor-4-androstene; 17.alpha.-Allyl-17-.beta.-hydroxy-.delta.(sup 4)-estren; 17.alpha.-Allyl-17.beta.-hydroxy-4-estrene; 17.alpha.-Allyl-3-deoxy-19-nortestosterone; 17.alpha.-Allyl-4-destrene-17.beta.-ol; 17.alpha.-Allyl-4-estren-17.beta.-ol; 17.alpha.-Allyl-4-oestrene-17.beta.-ol; 17.alpha.-Allylestr-4-en-17.beta.-ol; 17.alpha.-Allylestrenol; 17alpha-Allyl-17beta-hydroxy-4-estrene; 17alpha-Allyl-19-nor-delta-4-androstene-17beta-ol; 17alpha-Allyl-3-deoxy-19-nortestosterone; 17alpha-Allyl-4-destrene-17beta-ol; 17alpha-Allyl-4-estren-17beta-ol; 17alpha-Allyl-4-oestrene-17beta-ol; 17alpha-Allylestr-4-en-17beta-ol; 17alpha-Allylestrenol; 21-Methylene-19-nor-17-alpha-preg-4-en-17-ol; 3-Deoxy-17-alpha-allyl-19-nortestosterone
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Schizophrenia [ICD-11: 6A20] | Preclinical | [1] | |
| Company |
Akzo Nobel
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H32O
|
|||
| Canonical SMILES |
CC12CCC3C(C1CCC2(CC=C)O)CCC4=CCCCC34
|
|||
| InChI |
1S/C21H32O/c1-3-12-21(22)14-11-19-18-9-8-15-6-4-5-7-16(15)17(18)10-13-20(19,21)2/h3,6,16-19,22H,1,4-5,7-14H2,2H3/t16-,17+,18+,19-,20-,21-/m0/s1
|
|||
| InChIKey |
ATXHVCQZZJYMCF-XUDSTZEESA-N
|
|||
| CAS Number |
CAS 432-60-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
94016, 583200, 7848437, 9386954, 24702337, 30035228, 46506946, 48415534, 49832963, 49965886, 50767857, 53790158, 57400271, 71840264, 103811032, 104460203, 117557152, 134974162, 135805927, 137003638, 140185530, 143492475, 144205271, 152104357, 152164232, 152235876, 160964699, 163624663, 164815920, 172089080, 179316824, 184552229, 184812038, 198956599, 206246428, 223441641, 226666480, 242588146, 249865152
|
|||
| ChEBI ID |
CHEBI:31189
|
|||
| SuperDrug ATC ID |
G03DC01
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glycine transporter GlyT-1 (SLC6A9) | Target Info | Blocker | [2] |
| Reactome | Na+/Cl- dependent neurotransmitter transporters | |||
| WikiPathways | NRF2 pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Receptor binding of allylestrenol, a progestagen of the 19-nortestosterone series without androgenic properties. J Steroid Biochem. 1985 Aug;23(2):165-8. | |||
| REF 2 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.